The Medicines Co.
www.themedicinescompany.com
Latest From The Medicines Co.
Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
In Vivo's Rough Guide On The State Of RNAi
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cardiovascular
- Infectious & Viral Diseases
- Inflammation
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- The Medicines Co.
- Senior Management
-
Mark Timney, CEO
Chris Visioli, CFO
Diane Sullivan, Chief Commercial Officer
Peter Wijngaard, PhD, Chief Dev. Officer - Contact Info
-
The Medicines Co.
Phone: (973) 290-6000
8 Sylvan Way
Parsippany, NJ 07054
USA